Daily Archives: April 3, 2024

Clarity enters into Cu-67 SAR-bisPSMA Clinical Supply Agreement with NorthStar supporting late-stage therapy trials

Sydney, Australia 4 April 2024 Highlights New Clinical Supply Agreement with NorthStar for the production of 67Cu-SAR-bisPSMA drug product ensures seamless product supply as Clarity plans for upcoming pivotal therapy trials. Uniquely provides large-scale manufacturing of both the therapeutic isotope (copper-67) and cGMP radiopharmaceutical product in the United States ready for shipment to clinical sites.…

Despatch of Retail Entitlement Offer Booklet

Sydney, Australia 4 April 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”) announced on Tuesday, 26 March 2024, a fully underwritten pro rata accelerated non-renounceable entitlement offer (“Entitlement Offer”) to eligible shareholders to subscribe for one (1) new fully paid ordinary Clarity share (“New Share”) for every thirty three (33) existing fully paid ordinary Clarity…